Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-12-09 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第五次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the pre-approval of an agenda item for the upcoming board meeting about appointing an audit firm for the company's 2022 financial and internal control audit. It references regulatory guidelines and the company's governance rules. The document is short (559 characters) and does not contain actual financial statements or audit results, but rather an opinion on a proposed audit engagement. This fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is a pre-approval opinion and not the audit report itself, it is best classified as Audit Report / Information (AR). FY 2022
2022-12-09 Chinese
独立董事关于第四届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Lingkang Pharmaceutical Group Co., Ltd. regarding the proposal to appoint Zhongshen Zhonghuan CPA Firm as the auditor for the 2022 fiscal year. It references compliance with regulatory guidelines and company bylaws, and it is dated December 8, 2022. The document does not contain actual financial statements or detailed audit results but rather an opinion on an agenda item related to audit firm appointment to be submitted to the shareholders' meeting. It is not a full audit report or annual report but an independent directors' opinion on a board meeting matter. This fits best under 'Board/Management Information (MANG)' as it relates to board decisions and management matters concerning auditor appointment.
2022-12-09 Chinese
监事会议事规则（2022年12月修订）
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for Lingkang Pharmaceutical Group Co., Ltd. It details the procedures, rules, and governance related to the supervisory board meetings, including meeting types, proposal procedures, voting, record keeping, and execution of resolutions. There is no financial data, no mention of financial results, no regulatory filings or announcements, and no indication of it being a report or announcement of a report. The content is focused on internal governance rules and procedures for the supervisory board, which fits the definition of Governance Information (CGR). The document length is 2962 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2022-12-09 Chinese
关于变更会计师事务所公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the change of the company's accounting firm for the 2022 fiscal year. It details the new auditor's qualifications, the reasons for the change, communication with the previous auditor, and the approval process by the board and independent directors. There are no financial statements or audit reports included, only information about the auditor change and related procedural details. The document length is 3582 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates specifically to audit firm change information and audit-related disclosures, but is not a full annual report or audit report itself. However, given the short length and nature, it could also be considered a Regulatory Filing (RNS), but the content is focused on audit information, so AR is more precise. FY 2022
2022-12-09 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the fourth board of directors of Lingkang Pharmaceutical Group Co., Ltd. It details the meeting's convening, attendance, and the approval of various proposals including the appointment of an audit firm and amendments to internal rules and management systems. The document also notes that these proposals will be submitted to the company's second extraordinary general meeting of shareholders for approval. The content focuses on board meeting decisions and governance matters rather than financial results, audit reports, or shareholder voting outcomes. The document length is about 2003 characters, which is relatively short and consistent with a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-12-09 Chinese
信息披露事务管理制度（2022年12月修订）
Governance Information Classification · 95% confidence The document is titled '信息披露事务管理制度' which translates to 'Information Disclosure Management System' for Lingkang Pharmaceutical Group Co., Ltd. It is a detailed internal policy document outlining the company's procedures, responsibilities, and regulations regarding information disclosure. It covers definitions, general provisions, types of reports (annual, interim, quarterly), temporary reports, major event disclosures, internal reporting, confidentiality, financial management, investor relations, and penalties. It does not contain actual financial data, financial statements, audit opinions, or earnings results. Instead, it is a governance and procedural document about how the company manages and discloses information to comply with regulatory requirements. Therefore, it fits best under Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices.
2022-12-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.